Welcome to our dedicated page for Sana Biotechnology SEC filings (Ticker: SANA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sana Biotechnology, Inc. filings document the regulatory record for a public biotechnology company developing engineered-cell medicines. Recent 8-K reports disclose operating results, corporate presentations, program updates for UP421, SC451, and SG293, at-the-market common stock sales arrangements, executive appointments, and board-class governance matters.
Proxy materials describe annual meeting voting items, director elections, board structure, executive compensation, and stockholder governance procedures. The company’s filings also capture material agreements, capital-structure disclosures, Regulation FD presentations, and other event reports tied to its cell-therapy pipeline and public-company obligations.
Sana Biotechnology, Inc. provides an in-depth annual overview of its high-risk cell and gene engineering business, focused on treating diseases at their root cause with engineered cells. The company highlights substantial doubt about its ability to continue as a going concern and a need for additional funding to finance operations.
Sana’s lead ex vivo program, SC451, is a hypoimmune iPSC-derived pancreatic islet cell therapy aimed at type 1 diabetes, a condition affecting almost ten million people worldwide. First-in-human data with related product UP421 show HIP-modified allogeneic islet cells surviving and functioning 12 months without immunosuppression, with C‑peptide production and imaging evidence of graft survival.
Its lead in vivo program, SG293, uses a CD8-targeted fusogen to generate CD19 CAR T cells inside the body for B cell cancers and B cell mediated autoimmune diseases, supported by non‑human primate data showing robust CAR T generation and deep B cell depletion without lymphodepletion. The company has suspended other allogeneic CAR T trials to concentrate resources on SC451 and SG293, emphasizing significant scientific potential but heavy dependence on future clinical success, regulatory approvals, and new capital.
Sana Biotechnology entered an amended at-the-market sales agreement that will support a new Form S-3 registration for up to $150.0 million of common stock, with TD Cowen as sales agent earning up to 3.0% of gross proceeds.
The company reported 2025 cash, cash equivalents, and marketable securities of $138.4 million and expects its cash runway to extend into late 2026. GAAP net loss was $244.2 million for 2025, improved from $266.8 million in 2024, with non-GAAP net loss of $170.1 million. Research and development and general and administrative expenses declined meaningfully after a 2024 portfolio prioritization, partly offset by a $44.6 million impairment tied to reduced internal manufacturing build-out.
Operationally, Sana highlighted encouraging type 1 diabetes data from UP421, progress toward an IND for SC451, and advancement of in vivo CAR T candidate SG293, along with appointments including a new Chief Financial Officer and total 2025 equity gross proceeds of $133.7 million.
Piper Brian reported acquisition or exercise transactions in this Form 4 filing.
Sana Biotechnology, Inc. reported that EVP and Chief Financial Officer Brian Piper received new equity awards. He was granted 200,000 restricted stock units, each representing a right to receive one share of common stock, and a stock option for 900,000 shares.
The restricted stock units vest in four equal installments on February 17 of 2027, 2028, 2029 and 2030, if he continues providing service through each date. The stock option vests as to 25% of the shares on February 17, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, also subject to continued service.
Sana Biotechnology EVP and CFO Brian Piper filed an initial Form 3 insider report. This filing establishes his status as a reporting insider of Sana Biotechnology, Inc. It does not list any buy or sell transactions and serves as a baseline disclosure of his beneficial ownership reporting obligations.
Sana Biotechnology appointed Brian Piper as Executive Vice President, Chief Financial Officer, Treasurer, and Principal Financial Officer effective February 17, 2026, replacing CEO Steve Harr in the acting principal financial officer role. Piper brings over 25 years of biopharmaceutical finance experience, including CFO roles at Scorpion Therapeutics, Antares Therapeutics, Prelude Therapeutics, and Aevi Genomic Medicine, plus senior finance roles at Shire.
Under his offer letter, Piper will receive a $515,000 annual base salary, a target bonus equal to 40% of base salary, an option to purchase 900,000 shares with a four-year vesting schedule, and 200,000 RSUs vesting over four years, all subject to continued service. If terminated without cause or he resigns for good reason outside a change-in-control window, he is eligible for nine months of salary continuation and up to nine months of COBRA coverage, subject to a release of claims. He also participates in Sana’s Change in Control Severance Plan.
BlackRock, Inc. has filed a Schedule 13G reporting a passive ownership stake in Sana Biotechnology Inc. common stock. BlackRock reports beneficial ownership of 13,643,304 shares, representing 5.1% of Sana’s outstanding common stock as of the event date.
BlackRock has sole voting power over 13,405,747 shares and sole dispositive power over 13,643,304 shares, with no shared voting or dispositive power. The filing explains that these shares are held across certain BlackRock business units in the ordinary course of business, and that the position is not intended to change or influence control of Sana.
The disclosure notes that various underlying persons have rights to receive dividends or sale proceeds from the shares, but that no single such person has an interest in more than 5% of Sana’s total outstanding common stock.
Sana Biotechnology, Inc. furnished an updated corporate presentation tied to its appearance at the 44th Annual J.P. Morgan Healthcare Conference. The company highlighted progress across its cell therapy platforms, including UP421, a primary pancreatic islet cell therapy using its hypoimmune platform, which at 12 months post-transplant in a type 1 diabetes patient without immunosuppression continued to survive, evade immune detection, and function.
The company also stated it remains on track to file an investigational new drug application and begin a Phase 1 trial for SC451, a hypoimmune-modified, iPSC-derived pancreatic islet cell therapy, as early as this year, and announced a goal of generating initial human data for SG293, an in vivo CD19-directed CAR T cell therapy, as early as this year. The information is furnished under Regulation FD and is not deemed filed or incorporated into other SEC reports unless specifically referenced.
Sana Biotechnology director Hans Edgar Bishop reported an equity award. On January 5, 2026, he acquired 6,157 shares of Common Stock in a transaction coded "A" for acquisition. The footnote explains these consist of fully vested restricted stock units, with a reported price of $0.00 per share, indicating no cash purchase. After this grant, Bishop is shown as beneficially owning 5,840,740 shares of Sana Biotechnology common stock in direct ownership.
Sana Biotechnology, Inc. officer Susan D. Wyrick, identified as Acting Chief Financial Officer and Principal Accounting Officer, reported equity transactions involving company stock. On January 2, 2026, 7,500 restricted stock units were converted to common stock at $0.00 per share, reflecting previously granted compensation that vested 40% on January 2, 2025 and 60% on January 2, 2026. The corresponding RSU award balance went to zero after this conversion.
On January 5, 2026, Wyrick reported a transaction coded "F" involving 2,407 shares of common stock at $4.27 per share, after which she directly held 185,883 shares of Sana Biotechnology common stock.
Sana Biotechnology, Inc. officer Susan D. Wyrick reported activity in company stock. On December 13, 2025, 3,400 restricted stock units vested and converted into common stock at a price of $0.00 per share, increasing her directly held shares. On December 15, 2025, she disposed of 873 shares at $5.22 per share, after which she held 180,790 shares of common stock directly. The filing notes that the restricted stock unit award vested in full on December 13, 2025 and identifies Wyrick as Acting Chief Financial Officer and Principal Accounting Officer.